Literature DB >> 18954962

Intranasal fentanyl for episodic breathlessness.

Thomas Sitte, Claudia Bausewein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18954962     DOI： 10.1016/j.jpainsymman.2008.08.002

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN： 0885-3924            Impact factor:   3.612


× No keyword cloud information.
  10 in total

1.  Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Minjeong Park; Janet Williams; Diane Liu; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2016-07-09       Impact factor: 3.612

2.  Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Susan Frisbee-Hume; Minjeong Park; Diane Liu; Diwakar D Balachandran; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2017-08-10       Impact factor: 3.612

3.  Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial.

Authors:  David Hui; Angela Xu; Susan Frisbee-Hume; Gary Chisholm; Margarita Morgado; Suresh Reddy; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2013-07-03       Impact factor: 3.612

4.  Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients.

Authors:  Miguel Angel Benítez-Rosario; Inmaculada Rosa-González; Enrique González-Dávila; Emilio Sanz
Journal:  Support Care Cancer       Date:  2018-06-18       Impact factor: 3.603

Review 5.  [Nasal application of fentanyl citrate as symptom control against breathlessness in palliative care--overview and case report].

Authors:  Thomas Sitte
Journal:  Wien Med Wochenschr       Date:  2009-12

6.  Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany.

Authors:  Steffen T Simon; Anna Maria Niemand; Hamid Benalia; Raymond Voltz; Irene J Higginson; Claudia Bausewein
Journal:  J Palliat Med       Date:  2012-10-24       Impact factor: 2.947

Review 7.  Opioids for management of episodic breathlessness or dyspnea in patients with advanced disease.

Authors:  Luis Cabezón-Gutiérrez; Parham Khosravi-Shahi; Sara Custodio-Cabello; Francisco Muñiz-González; Maria Del Puerto Cano-Aguirre; Soledad Alonso-Viteri
Journal:  Support Care Cancer       Date:  2016-06-22       Impact factor: 3.603

8.  Intranasal fentanyl for pain control: current status with a focus on patient considerations.

Authors:  Eric Prommer; Lisa Thompson
Journal:  Patient Prefer Adherence       Date:  2011-03-18       Impact factor: 2.711

9.  Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions.

Authors:  Lucas Pieper; Julia Wager; Boris Zernikow
Journal:  BMC Palliat Care       Date:  2018-09-10       Impact factor: 3.234

10.  Fentanyl nasal spray in a patient with end-stage COPD and severe chronic breathlessness.

Authors:  Daisy J A Janssen; Marieke H J van den Beuken-van Everdingen; Cornelia A Verberkt; Jacques P H M Creemers; Emiel F M Wouters
Journal:  Breathe (Sheff)       Date:  2019-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.